Related Experiment Video

Updated: Jun 6, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K

Dissecting the novel molecular interactions of solute carrier family 4 member 4 (SLC4A4) for prostate cancer (PCa)

Asif Rashid1,2, Hiu Ling Fung3, Alexander Hin Ning Tang4

  • 1Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China. arashid2@hku.hk.

Scientific Reports
|November 25, 2024
PubMed

Insights

Solute carrier family 4 member 4 (SLC4A4) expression is higher in low-grade prostate cancer (PCa). Targeting SLC4A4 may impede PCa progression by affecting key signaling pathways involved in tumor growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer (PCa) is a leading malignancy in men.
  • Understanding the molecular drivers of PCa progression is crucial for developing effective therapies.
  • The role of solute carrier family 4 member 4 (SLC4A4) in PCa remains largely unexplored.

Purpose of the Study:

  • To elucidate the molecular pathways regulated by SLC4A4 in prostate cancer progression.
  • To investigate the functional significance of SLC4A4 in PCa cell behavior.

Main Methods:

  • Analysis of clinical prostatic acinar adenocarcinoma specimens.
  • Investigated SLC4A4 expression levels in different grades of PCa.
  • Utilized SLC4A4 knockdown (shSLC4A4) in PCa cells (DU145).
  • Examined signaling pathways including SLC4A4/GSK-3β/β-catenin and SLC4A4/RB axis.
  • Performed transcriptome sequencing.

Main Results:

  • Higher SLC4A4 expression was observed in low-grade PCa.
  • SLC4A4 knockdown reduced tumor growth, invasion, and migration.
  • Disruption of the SLC4A4/GSK-3β/β-catenin axis led to reduced β-catenin levels.
  • SLC4A4 knockdown affected the SLC4A4/RB axis, causing cell cycle arrest.
  • Transcriptome analysis revealed SLC4A4 regulates differentiation and metabolic pathways.

Conclusions:

  • SLC4A4 plays a significant role in prostate cancer progression.
  • The SLC4A4/GSK-3β/β-catenin and SLC4A4/RB signaling pathways are critical for PCa.
  • SLC4A4 inhibition demonstrates potential for retarding tumor growth and metastasis.
  • SLC4A4 represents a potential therapeutic target for prostate cancer.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K